Description

Aflibercept CAS NO 845771-78-0 is a recombinant fusion protein designed as a potent vascular endothelial growth factor (VEGF) inhibitor. This compound is of critical importance in the development of targeted anti-angiogenic therapies, offering a high-affinity mechanism to block pathological blood vessel growth. It is primarily required by the biopharmaceutical and research sectors for the formulation of advanced ophthalmic and oncological treatments, including for conditions like wet age-related macular degeneration and metastatic colorectal cancer.

Application

• Active Pharmaceutical Ingredient (API) in the manufacture of intravitreal injections for ophthalmic use.
• Key Biologic Component in the development and production of anti-cancer therapeutics targeting tumor angiogenesis.
• Reference Standard for quality control and analytical method development in pharmaceutical R&D laboratories.
• Research Reagent for preclinical studies investigating VEGF signaling pathways and angiogenesis inhibition.
• Biosimilar Development, serving as the benchmark molecule for comparative structural and functional analyses.
• Formulation Studies for optimizing drug delivery systems, stability, and bioavailability of biologic drugs.

Basic Information

Product Name	Aflibercept
CAS No.	845771-78-0
Molecular Formula	C4318H6788N1164O1304S32
Molecular Weight	96.9 kDa (Approx.)
Synonyms	VEGF Trap; Aflibercept (VEGF Trap); Recombinant Fusion Protein VEGF Trap; Eylea (Brand Name); Zaltrap (Brand Name); VEGF Receptor Fusion Protein; Vascular Endothelial Growth Factor Trap; Anti-VEGF Fusion Protein
EINECS	Contact for details

Quality Control

Our Aflibercept is manufactured under stringent quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity and potency, SDS-PAGE and CE-SDS for identity and impurity profile, and endotoxin and sterility testing as applicable. We adhere to cGMP guidelines to ensure product consistency and reliability for critical research and development applications. A detailed Certificate of Analysis (COA) is provided with each shipment.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized powder at -20°C or below. Reconstituted solutions should be handled aseptically and used immediately or stored according to validated stability protocols, typically at 2-8°C for short periods. The product is hygroscopic (moisture-sensitive); ensure containers are sealed under controlled humidity conditions.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear solution
Identification (SDS-PAGE/CE)	Conforms to reference standard
Purity (SEC-HPLC)	≥ 98.0% (Monomer)
Potency (Cell-based Assay)	≥ 95.0% of reference standard
Protein Content (UV/A280)	95.0 - 105.0% of label claim
Endotoxin	< 1.0 EU/mg
Residual Moisture (KF)	≤ 3.0%
pH (for solution)	6.0 - 7.5

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.